PDCD1 and neoplasm: Recent clinical studies targeting co-inhibitory and co-stimulatory immune checkpoints such as cytotoxic T lymphocyte protein-4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand (PD-L1) have demonstrated anti-tumour activity in several cancer types [3–6].